argenx planning NASDAQ listing

Antibody engineering company argenx N.V. (Euronext:ARGX) filed to raise up to $74.8 million in a public offering of ADSs on NASDAQ underwritten by Cowen, Piper Jaffray, JMP Securities and Wedbush PacGrow.

argenx's lead candidate, ARGX-113, is in separate Phase II trials to treat myasthenia gravis and primary immune thrombocytopenia. The human antibody Fc fragment, which argenx developed using its ABDEG technology, targets the Fc fragment of IgG receptor transporter alpha (FCRN; FCGRT)...